An integrated characterization of serological, pathological, and functional events in doxorubicin-induced cardiotoxicity

Laura Cove-Smith, Neil Woodhouse, Adam Hargreaves, Jason Kirk, Susan Smith, Sally A. Price, Melanie Galvin, Catherine J Betts, Simon Brocklehurst, Alison Backen, John Radford, Kim Linton, Ruth Roberts, Matthias Schmitt, Caroline Dive, Jonathan D Tugwood, Paul D. Hockings, Howard R. Mellor

Research output: Contribution to journalArticlepeer-review

28 Citations (Scopus)


Many efficacious cancer treatments cause significant cardiac morbidity, yet biomarkers or functional indices of early damage, which would allow monitoring and intervention, are lacking. In this study, we have utilized a rat model of progressive doxorubicin (DOX)-induced cardiomyopathy, applying multiple approaches, including cardiac magnetic resonance imaging (MRI), to provide the most comprehensive characterization to date of the timecourse of serological, pathological, and functional events underlying this toxicity. Hannover Wistar rats were dosed with 1.25 mg/kg DOX weekly for 8 weeks followed by a 4 week off-dosing “recovery” period. Electron microscopy of the myocardium revealed subcellular degeneration and marked mitochondrial changes after a single dose. Histopathological analysis revealed progressive cardiomyocyte degeneration, hypertrophy/cytomegaly, and extensive vacuolation after two doses. Extensive replacement fibrosis (quantified by Sirius red staining) developed during the off-dosing period. Functional indices assessed by cardiac MRI (including left ventricular ejection fraction (LVEF), cardiac output, and E/A ratio) declined progressively, reaching statistical significance after two doses and culminating in “clinical” LV dysfunction by 12 weeks. Significant increases in peak myocardial contrast enhancement and serological cardiac troponin I (cTnI) emerged after eight doses, importantly preceding the LVEF decline to <50%. Troponin I levels positively correlated with delayed and peak gadolinium contrast enhancement, histopathological grading, and diastolic dysfunction. In summary, subcellular cardiomyocyte degeneration was the earliest marker, followed by progressive functional decline and histopathological manifestations. Myocardial contrast enhancement and elevations in cTnI occurred later. However, all indices predated “clinical” LV dysfunction and thus warrant further evaluation as predictive biomarkers.
Original languageEnglish
Pages (from-to)3-15
Number of pages13
JournalToxicological Sciences
Issue number1
Early online date27 Mar 2014
Publication statusPublished - 1 Jul 2014


  • doxorubicin
  • cardiotoxicity
  • chemotherapy
  • cardiac MRI
  • anthracycline
  • ejection fraction


Dive into the research topics of 'An integrated characterization of serological, pathological, and functional events in doxorubicin-induced cardiotoxicity'. Together they form a unique fingerprint.

Cite this